John M. Fastenau, M.P.H., R.Ph.
John is a Senior Director in Health Economics and Outcomes Research at Janssen where he leads a team of researchers responsible for conducting non-interventional studies supporting the neuroscience and infectious disease franchises. The group is active publishing research with a focus on the economic burden of disease, adherence to treatment, improvement in continuity of care, and tools to inform decision-making. John has worked for several multi-national organizations including Novartis, Merck, and Johnson & Johnson in roles supporting both US and global markets. He has collaborated on research projects with leaders in academia and the public sector. John received his Bachelors of Science in Pharmacy from Rutgers University and his Masters in Public Health from Boston University. He completed a two-year fellowship program in health economics sponsored by Novartis and Thomas Jefferson University (TJU) and is a doctorate student in health policy at TJU.
Pauline McNulty, Ph.D.
Pauline McNulty is Vice President, Global Market Access and Commercial Strategy Operations at Janssen Pharmaceutical Companies of Johnson & Johnson. In that role, she is responsible for ensuring the patient’s perspective is appropriately incorporated into global drug development programs through measurement of Patient- Reported Outcomes (PROs). In addition, for the past three years, she has been leading an effort to design and implement a Market Access Leadership and Development Program within Global Market Access. Pauline joined Johnson & Johnson in 1994 as a Director in the Health Economics department. Since that time, she has held positions of broad and increasing responsibility, including Vice President Health Economics, when she was responsible for health economics for all products in development, and Vice President Health Economics & Pricing when she was responsible for market access for products in the Internal Medicine portfolio. Previously, Pauline worked at Schering-Plough, where she was Director Pharmacoeconomics for Respiratory and Cardiovascular products in development as well as those already on the market. Prior to joining the pharmaceutical industry, she worked for a healthcare research and consulting company, SysteMetrics, in Santa Barbara, California. Pauline received her Ph.D. in experimental psychology from the University of California, Santa Barbara. She has an MSc in Experimental Psychology and a BSc from University College Dublin. She has published several articles related to health economics and patient- reported outcomes and the patient’s perspective in drug treatment.
In 2009-2010, Pauline served as a member of the Steering Committee for the National Quality Forum’s (NQF) National Voluntary Consensus Standards for Patient Outcomes. She participated in Johnson & Johnson’s Health Policy Excellence Program through the Jefferson School of Population Health (2009-2011).
Catherine Tak Piech, MBA
Catherine Tak Piech is currently Vice President, Health Economics & Outcomes Research (HECOR), at Janssen Scientific Affairs LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. She leads a multidisciplinary team of scientists engaged in the development and dissemination of evidence on the comparative value of the company’s treatments to support informed decision-making by payers, providers and patients, as well as related access and affordability topics and health policy research.
Her 30-year pharmaceutical industry career spans pre-clinical research, commercial analytics, pricing, and health economics & outcomes research. Catherine came to Johnson & Johnson in March 1997 to join Global Health Economics & Pricing, where she directed pricing research and strategy across multiple therapeutic areas. She then joined Ortho Biotech in April 2002 as Executive Director, Outcomes Research, and built up the department’s research capabilities and capacity, resulting in her promotion to Vice President in late 2004. Next, she integrated the Outcomes Research groups from both Centocor and Ortho Biotech as those companies merged. Catherine was named to her current position in July 2009 and was tasked with creating a Health Economics & Outcomes Research Center of Excellence that spans the entire Janssen pharmaceutical portfolio in the US. During her tenure at Johnson & Johnson, Catherine has been recognized with multiple Standards of Leadership and performance awards, and was also a recipient of a Rising Star Award from the Healthcare Businesswomen’s Association in 2006, and a TWIN (Tribute to Women in Industry) honoree in 2009.
Catherine received her BA in Microbiology from Rutgers University and her MBA, with Honors, from Boston University Graduate School of Management. She has also studied Medical Humanities at Drew University in Madison, New Jersey, and holds a certificate in Health Policy from the Jefferson School of Population Health in Philadelphia. She has a longstanding special interest in the influence of cultural values on health care policy and variation in willingness to pay.
Kristijan Kahler, R.Ph., Ph.D.
I head the Global Outcomes Evidence & Analytics team which is a diverse group of Analytic Leads that provide expertise on the design and conduct of Non-Interventional Studies (NIS) conducted both internally and externally within Global Medical Affairs as well as Global Patient Access. One of our primary roles is to utilize in-house capabilities to execute NIS using large patient level healthcare databases. Other responsibilities of the group include providing broad analytical and methodological expertise, scientific governance for NIS, and training and development on the use of real world healthcare data.
I have been with Novartis since 2001. My initial position was with the US HEOR group where I was responsible for the development and implementation of HEOR strategies for both marketed and development products across various disease areas. In 2009, I started the Outcomes Research Methods & Analytics team with the US HEOR organization, and then moved to my current role in Global at the end of 2012.
Prior to Novartis I spent about 4 years in the Worldwide Outcomes Research department at Merck & Co.
I hold a Ph.D. in Epidemiology from the UMDNJ School of Public Health; a Master’s degree in Epidemiology from the Harvard School of Public Health, and a Bachelor’s degree in Pharmacy from the University of Rhode Island.
I enjoy sports, fitness, good food, and good company.
Simu Thomas, PhD
Dr. Simu K. Thomas is the Global Head and Executive Director of Health Economics Modeling at Novartis. With more than 15 years of experience as a Health Economist, he leads a multidisciplinary team and affiliated experts to lead the development and execution of health economics strategies for Novartis. Prior to this role, he was the Global Head for health economics/outcomes research for Neuroscience and Ophthalmics franchises of Novartis. He has worked throughout North America, Europe and Asia and has considerable experience and knowledge of the health care systems in those regions.
Dr. Simu has authored more than 30 peer reviewed manuscripts and 60 congress presentations and co-authored book chapters in the field of Pharmacoeconomics. He is also a member delegate to the ISPOR Institutional Council. He has a PhD in Pharmaceutical Economics from the University of Maryland, MS in Pharmacy Administration from the University of Toledo and Pharmacy degrees from Birla Institute of Technology & Science, Pilani, India. Dr. Simu also serves as Adjunct Assistant Professor at University of Maryland, USA.
Patricia Sacco, M.P.H., R.Ph.
Patty entered the field of drug research and discovery immediately following graduation from Rutgers College of Pharmacy in 1983. Experience as a clinical monitor provided the foundation for a deep interest in understanding outcomes of drug interventions, beyond safety and efficacy. She transitioned to the long-term care industry to deepen her clinical skills in geriatrics and pediatrics, which also provided her the opportunity to interact directly with patients, clinicians and pharmaceutical industry colleagues to conduct small scale outcomes studies. After obtaining her MPH, she moved to a career in the pharmaceutical industry. Investing 3+ years in clinical research at Novartis sharpened her research skills and provided her the opportunity to move to a role in the health economics and outcomes research group. Her extensive clinical experience in the long term care industry for 18+ years is a key strength in translating results from clinical trials to meaningful real world outcomes for patients, physicians and payers. She has a special interest in neuroscience, rare diseases and Alzheimer’s Disease, and has worked globally with HEOR, development and commercial colleagues on evidence generation for reimbursement and market access of Novartis compounds.
She volunteers as a member of two boards that address the needs of individuals with disabilities; professionally she is active within The International Society of Pharmacoeconomics and Outcomes Research (ISPOR).
Zeba M. Khan, Ph.D, MS
Dr. Zeba Khan joined Celgene Corporation based in Summit, New Jersey as Vice President of Global Pricing and Market Access and established the function in 2008, and is currently Vice President of Global Strategic Market Access & Policy. She led the development and implementation of pricing, health economics, outcomes research, and market access strategies and policies for all therapeutic areas from early development through life cycle management. Celgene is a $25+ billion market capitalization, NASDAQ-listed, leading global biopharmaceutical company.
Prior to joining Celgene Corporation, Dr. Khan held various positions at Novartis including Global Head of Pricing and Health Economics, CVM in Basel, Switzerland and Executive Director, Head of Pricing Strategy and Policy in East Hanover, New Jersey. Prior to joining Novartis, she held various leadership roles in Heathcare Management and Health Economics and Outcomes Research at GlaxoSmithKline in Research Triangle Park, North Carolina. Prior to joining the pharmaceutical industry, Dr. Khan was a clinical pharmacist at the University of Utah Health Sciences Center in Salt Lake City, Utah.
Dr. Khan serves on the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Board of Directors and is currently the ISPOR Treasurer. She has been an active member of ISPOR since 1996 serving on many committees including Chair of the ISPOR Short Course Committee, ISPOR Institutional Council, and the Student Network Faculty Advisor. Dr. Khan serves on the Board of Directors of the New Jersey Crossroads Chapter of the American Red Cross and is currently the Board Chair. Dr. Khan also serves on the University of Washington School of Pharmacy Corporate Advisory Board and on the Rutgers Health Economics and Outcomes Research Graduate Program Corporate Advisory Board. She is active with several other professional and non-profit organizations.
Dr. Khan earned her pharmacy degree from the University of Utah and her M.S. and Ph.D. in Pharmacoeconomics / Health Economics & Outcomes Research from The University of Texas at Austin. Over her 23-year career, she has authored/co-authored over 90 publications and podium/poster presentations in the health services research field.
Joe DiCesare, MPH
Joe DiCesare is Global Head of Strategic Pricing and Access in the Oncology business unit at Novartis Pharmaceuticals. Joe’s team is responsible for developing global pricing strategies for Novartis Oncology products and monitoring evolving market access trends and healthcare systems around the world. He also leads the Oncology real world evidence capabilities and the patient-reported outcomes team.
Prior to moving into his current role, he led the U.S. and the Global Health Economics & Outcomes Research departments at Novartis between 1999 and 2012. Joe also worked for 11 years in clinical development at Knoll (Abbott) Pharmaceuticals and at Sandoz/Novartis Pharmaceuticals.
Joe received his Pharmacy degree from Rutgers University and a Masters in Public Health focused in epidemiology from the UMDNJ School of Public Health. He is also an Adjunct Assistant Professor at Rutgers College of Pharmacy.
Bryan M. Johnstone, PhD
Bryan M. Johnstone, Ph.D., is Vice President, Evidence-Based Medicine, North America Medical Affairs, at Sanofi US. Dr. Johnstone joined the pharmaceutical industry in 1996. Prior to joining Sanofi in 2010, he held various scientific and leadership roles in the health outcomes and medical divisions at Eli Lilly and Company, including head of U.S. Outcomes Research and head of Global Phase IIIB/IV Outcomes Research. Dr. Johnstone received his doctorate from the University of Arizona and previously held academic appointments at the University of California at San Francisco medical center and the University of Kentucky College of Medicine. He is a former NIH Principal Investigator with primary research interests in the diabetes, neuroscience, and cardiovascular therapeutic areas. His primary methodological areas of interest are meta-analysis and longitudinal data analysis.
Robert J. Matheis, PhD, MA, CMPP
Robert J. Matheis is Executive Director and Head of Global Scientific Communications with Celgene Corporation and Past President of the International Society for Medical Publication Professionals (ISMPP), a global organization providing education, best practices, and advocacy for medical publication professionals.
Dr. Matheis has over 15 years of research and communication experience, spanning both government and industry. Trained as a psychologist, he has conducted research, provided treatment, and instructed within a variety of clinical and academic capacities related to brain and spinal cord injury, multiple sclerosis, diabetes and other neurocognitive disorders. He has an extensive bibliography of scientific congress presentations and peer-review publications across various disease states, in addition to research and publication accomplishments in alternative medicine and psychosocial factors impacting healthcare.
Through his various roles, Dr. Matheis has actively advocated for the evolution of communication tools that deliver and translate medical evidence for use by health care decision makers, providers, and patients. He currently is exploring innovative communication channels that seek to leverage new technologies in communicating medical information to healthcare stakeholders.
Dr. Matheis is a licensed clinical psychologist and founder of Psychological and Educational Consulting LLC. He holds a PhD in clinical/neuro psychology, a MA in behavioral statistics, and BA in psychology.
Anita Burrell, MBA, MA
Anita Burrell is currently Associate Vice President, Commercial Operations Effectiveness in the Global Diabetes Division of Sanofi based in Bridgewater, USA. She is responsible for the portfolio strategic discussion and execution in key markets for the diabetes franchise.
Anita has over 20 years of experience in the pharmaceutical industry in a wide variety of roles. Prior to this latest role she was the R&D Project Lead for Aubagio, the oral MS therapy which has been successfully submitted and launched in over 30 markets worldwide.
Anita joined the pharmaceutical industry as a pioneer in the field of Health Economics and led the UK HE department before moving into increasing senior roles within the discipline. In 2005 – 2009 Anita was based in Paris as the Head of the Global Health Economics and Reimbursement Division for Sanofi with responsibility for market access support for all major products across the portfolio.
Anita holds a BA (Hons) in Economics from the University of Stirling, an M.A. in Economics from Dalhousie University, Nova Scotia, Canada, and a Masters in Business Administration from Kingston University, Surrey UK.
Jianwei Xuan, PhD
Dr. Jianwei Xuan is currently Director and Professor in the Health Economic Research Institute at Sun Yat-sen University. Dr. Jianwei Xuan has more than 20 years of research, teaching, and global leadership experience in major Universities such as Sun Yat-sen University，University of Florida, Fudan University, and several multinational pharmaceutical companies such as Pfizer, GSK, etc. Jianwei has led multiple global health economic and market access teams and conducted high impact health policy, health economics, comparative effectiveness, outcomes research, epidemiology and market access researches to support evidence-based decision-making process. Research results have been adapted in numerous countries to support formulating national health care policy, designing drug reimbursement formulary and supporting government decision making. Before entering industry, he worked as medical reviewers in China FDA for more than 6 years. Dr. Xuan is also very familiar with drug development process, global regulatory affair, and safety requirements.
With more than 20 years of working/research experience, Dr. Xuan also published extensively in health economic, market access and outcomes research areas. He has established extensive professional network with global key opinion leaders and led numerous global policy forums, advisory boards, and government/payer panel discussions. He is current Chair of ISPOR Asia consortium advisory committee. He also has extensive teaching and graduate student advising experience in advising Ph.D. students and training government officials, researchers, and various health care service researchers.
Dr. Xuan obtained his Ph.D. in Health Economics from School of Public Health, University of North Carolina at Chapel Hill and completed his medical degree in Shanghai Medical University, China.